ESR1 and breast carcinoma: Our group has initiated a multicenter randomized double-blind prospective clinical trial comparing the efficacy of tamoxifen as an adjuvant endocrine therapy in early-stage ERα/PR-/ERβ+ breast cancer patients (ClinicalTrials.gov Identifier:NCT02062489).